Your browser doesn't support javascript.
loading
CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes, Ryan M; Zhang, Chenghao; Deng, Yilun; Ji, Niannian; Mukherjee, Neelam; Padron, Alvaro S; Clark, Curtis A; Svatek, Robert S; Curiel, Tyler J.
Afiliação
  • Reyes RM; South Texas Medical Scientist Training Program, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Zhang C; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Deng Y; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Ji N; Xiangya Medical School, Central South University, Changsha, Hunan, China.
  • Mukherjee N; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Padron AS; Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Clark CA; Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Svatek RS; Division of Hematology/Oncology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Curiel TJ; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Oncoimmunology ; 10(1): 2006529, 2021.
Article em En | MEDLINE | ID: mdl-34858732
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Melanoma Experimental Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Melanoma Experimental Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article